βマンノース症、βマンノシドーシス
WordNet
- to remain unmolested, undisturbed, or uninterrupted -- used only in infinitive form; "let her be"
- work in a specific place, with a specific subject, or in a specific function; "He is a herpetologist"; "She is our resident philosopher" (同)follow
- have life, be alive; "Our great leader is no more"; "My grandfather lived until the end of war" (同)live
- be identical to; be someone or something; "The president of the company is John Smith"; "This is my house"
- happen, occur, take place; "I lost my wallet; this was during the visit to my parents house"; "There were two hundred people at his funeral"; "There was a lot of noise in the kitchen"
- have the quality of being; (copula, used with an adjective or a predicate noun); "John is rich"; "This is not a good answer"
- occupy a certain position or area; be somewhere; "Where is my umbrella?" "The toolshed is in the back"; "What is behind this behavior?"
- spend or use time; "I may be an hour"
- stake on the outcome of an issue; "I bet $100 on that new horse"; "She played all her money on the dark horse" (同)wager, play
- the act of gambling; "he did it on a bet" (同)wager
- maintain with or as if with a bet; "I bet she will be there!" (同)wager
- second in order of importance; "the candidate, considered a beta male, was perceived to be unable to lead his party to victory"
- the 2nd letter of the Greek alphabet
- preliminary or testing stage of a software or hardware product; "a beta version"; "beta software"
- beets (同)genus Beta
PrepTutorEJDIC
- 《連結語として補語を伴なって…『である』,…だ,…です / 《位置・場所を表す語句を伴って》(…に)『ある』,いる(occupy a place or situation) / 〈物事が〉『存在する』,ある(exist);〈生物が〉生存する,生きている(live) / 行われる,起こる,発生する(take place, occur) / 存続する,そのままでいる(remain as before) / 《『be to』 do》 / …する予定である,…することになっている / …すべきだ / 《受動態の不定詞を伴って》…できる / 《命令》…するのだ / 《条件節に》…する意図がある / 《『if…were to』 do》…するとしたなら / 《『be』 do『ing』》《進行形》 / 《進行中の動作》…している,しつつある / 《近い未来》…しようとしている,するつもり / 《動作の反復》(いつも)…している / 《『be』+『他動詞の過去分詞』》《受動態》…される,されている / 《『be』+『自動詞の過去分詞』》《完了形》…した[状態にある]
- 『かけ』・(…との)かけ《+『with』+『名』》 / かけた物(金) / かけの対象 / 〈金・物〉'を'『かける』 / (かけ事・ゲームなどで)〈人〉‘と'『かけをする』《+『名』〈人〉+『on』+『名』》 / (…に)『かける』《+『on』(『against』)+『名』(one's do『ing』)》
- ベータ(ギリシア語アルファベットの第2文字;B,β;英語のB,b に遭当)
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/03/31 01:00:05」(JST)
[Wiki en表示]
Beta-mannosidosis |
Classification and external resources |
OMIM |
248510 |
DiseasesDB |
34529 |
MeSH |
D044905 |
Beta-mannosidosis, also called lysosomal beta-mannosidase deficiency,[1] is a rare autosomal recessive[2] form of mannosidosis associated with MANBA.[3]
Beta-mannosidosis has an autosomal recessive pattern of inheritance.
References
- ^ Online 'Mendelian Inheritance in Man' (OMIM) 248510
- ^ Kleijer, Wj; Hu, P; Thoomes, R; Boer, M; Huijmans, Jg; Blom, W; Van, Diggelen, Op; Seemanova, E; Macek, M (1990). "Beta-mannosidase deficiency: heterogeneous manifestation in the first female patient and her brother". Journal of Inherited Metabolic Disease 13 (6): 867–72. doi:10.1007/BF01800211. PMID 2079835.
- ^ Uchino, Y; Fukushige, T; Yotsumoto, S; Hashiguchi, T; Taguchi, H; Suzuki, N; Konohana, I; Kanzaki, T (July 2003). "Morphological and biochemical studies of human beta-mannosidosis: identification of a novel beta-mannosidase gene mutation". The British journal of dermatology 149 (1): 23–9. doi:10.1046/j.1365-2133.2003.05365.x. PMID 12890191.
External links
- Mannosidosis, beta A, lysosomal at NIH's Office of Rare Diseases
(LSD) Inborn error of carbohydrate metabolism: glycoproteinosis (E77, 271.8)
|
|
Anabolism |
- Dolichol kinase deficiency
- Congenital disorder of glycosylation
|
|
Post-translational modification
of lysosomal enzymes |
- Mucolipidosis: I-cell disease/II
- Pseudo-Hurler polydystrophy/III
|
|
Catabolism |
- Aspartylglucosaminuria
- Fucosidosis
- mannosidosis
- Alpha-mannosidosis
- Beta-mannosidosis
- Sialidosis
- Schindler disease
|
|
Other |
- solute carrier family (Salla disease)
- Galactosialidosis
|
|
|
mt, k, c/g/r/p/y/i, f/h/s/l/o/e, a/u, n, m
|
k, cgrp/y/i, f/h/s/l/o/e, au, n, m, epon
|
m (A16/C10), i (k, c/g/r/p/y/i, f/h/s/o/e, a/u, n, m)
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Distribution and Severity of Neuropathology in β-Mannosidase-Deficient Mice is Strain Dependent.
- Lovell KL1, Zhu M, Drummond MC, Switzer RC 3rd, Friderici KH.Author information 1Department of Neurology and Ophthalmology, Michigan State University, 965 Fee Road, A502D East Fee Hall, East Lansing, MI, 48824, USA, lovell@msu.edu1.AbstractNeurological dysfunction is common in humans and animals with lysosomal storage diseases. β-Mannosidosis, an autosomal recessive inherited disorder of glycoprotein catabolism caused by deficiency of the lysosomal enzyme β-mannosidase, is characterized by intracellular accumulation of small oligosaccharides in selected cell types. In ruminants, clinical manifestation is severe, and neuropathology includes extensive intracellular vacuolation and dysmyelination. In human cases of β-mannosidosis, the clinical symptoms, including intellectual disability, are variable and can be relatively mild. A β-mannosidosis knockout mouse was previously characterized and showed normal growth, appearance, and lifespan. Neuropathology between 1 and 9 months of age included selective, variable neuronal vacuolation with no hypomyelination. This study characterized distribution of brain pathology in older mutant mice, investigating the effects of two strain backgrounds. Morphological analysis indicated a severe consistent pattern of neuronal vacuolation and disintegrative degeneration in all five 129X1/SvJ mice. However, the mice with a mixed genetic background showed substantial variability in the severity of pathology. In the severely affected animals, neuronal vacuolation was prominent in specific layers of piriform area, retrosplenial area, anterior cingulate area, selected regions of isocortex, and in hippocampus CA3. Silver degeneration reaction product was prominent in regions including specific cortical layers and cerebellar molecular layer. The very consistent pattern of neuropathology suggests metabolic differences among neuronal populations that are not yet understood and will serve as a basis for future comparison with human neuropathological analysis. The variation in severity of pathology in different mouse strains implicates genetic modifiers in the variable phenotypic expression in humans.
- JIMD reports.JIMD Rep.2013 Oct 20. [Epub ahead of print]
- Neurological dysfunction is common in humans and animals with lysosomal storage diseases. β-Mannosidosis, an autosomal recessive inherited disorder of glycoprotein catabolism caused by deficiency of the lysosomal enzyme β-mannosidase, is characterized by intracellular accumulation of small oligosa
- PMID 24142277
- Oligosaccharide analysis in urine by maldi-tof mass spectrometry for the diagnosis of lysosomal storage diseases.
- Xia B1, Asif G, Arthur L, Pervaiz MA, Li X, Liu R, Cummings RD, He M.Author information 1Department of Human Genetics, Emory University, 2165 N. Decatur Rd., Decatur, GA, 30033, USA.AbstractBACKGROUND: There are 45 known genetic diseases that impair the lysosomal degradation of macromolecules. The loss of a single lysosomal hydrolase leads to the accumulation of its undegraded substrates in tissues and increases of related glycoconjugates in urine, some of which can be detected by screening of free oligosaccharides (FOS) in urine. Traditional 1-dimensional TLC for urine oligosaccharide analysis has limited analytical specificity and sensitivity. We developed fast and robust urinary FOS and glycoaminoacid analyses by MALDI-time-of-flight/time-of-flight (MALDI-TOF/TOF) mass spectrometry for the diagnosis of oligosaccharidoses and other lysosomal storage diseases.
- Clinical chemistry.Clin Chem.2013 Sep;59(9):1357-68. doi: 10.1373/clinchem.2012.201053. Epub 2013 May 15.
- BACKGROUND: There are 45 known genetic diseases that impair the lysosomal degradation of macromolecules. The loss of a single lysosomal hydrolase leads to the accumulation of its undegraded substrates in tissues and increases of related glycoconjugates in urine, some of which can be detected by scre
- PMID 23676310
- A Clinically Severe Variant of β-Mannosidosis, Presenting with Neonatal Onset Epilepsy with Subsequent Evolution of Hydrocephalus.
- Broomfield A1, Gunny R, Ali I, Vellodi A, Prabhakar P.Author information 1Metabolic Medicine Unit, Hospital for Children with UCL Institute of Child Health, Great Ormond Street, London, UK, WC1N 3JH, alexander.broomfield@gosh.nhs.uk.Abstractβ-Mannosidosis results from a functional deficiency of the lysosomal enzyme, β-mannosidase. While being a well recognised, naturally occurring disease in both goats and cattle, it is an extremely rare disorder in humans with the first cases only being recorded in 1986. Until now the severity of the human disease has not mirrored that of its bovine or caprine counterparts, whose presentation is typically in the neonatal period with both altered skull morphology and seizures. Human β-mannosidosis has previously appeared to be a more indolent disease, with its only consistent phenotypic feature being developmental delay of varying severity. We report a patient, homozygous for a private mutation, who presented in the immediate perinatal period with seizures and who subsequently developed communicating hydrocephalus at 2 years of age.These are two new phenotypic features for β-mannosidosis. The first being the neonatal onset of the seizures, for while seizures have been seen in 3 out of the previous 20 documented cases, they have never before manifested prior to 6 months of age. However, as in the previous documented cases, the seizures were difficult to control and were associated with severe developmental delay.The second unique feature about this case was the development of communicating hydrocephalus. We discuss the possible mechanisms of its development.In summary, β-mannosidosis must thus now be considered in the differential diagnosis of neonatal onset seizures, and the potential for the development of hydrocephalus should be monitored during subsequent clinical follow-up.
- JIMD reports.JIMD Rep.2013;11:93-7. doi: 10.1007/8904_2013_227. Epub 2013 Apr 16.
- β-Mannosidosis results from a functional deficiency of the lysosomal enzyme, β-mannosidase. While being a well recognised, naturally occurring disease in both goats and cattle, it is an extremely rare disorder in humans with the first cases only being recorded in 1986. Until now the severity of th
- PMID 23588843
Related Links
- Beta Mannosidosis What is ß-Mannosidosis (Beta-Mannosidosis)? ß-Mannosidosis is one of seven identified Glycoprotein storage diseases. These inherited diseases are part of a larger group of disorders called Lysosomal storage ...
- Mutations in the MANBA gene cause beta-mannosidosis. The MANBA gene provides instructions for making the enzyme beta-mannosidase. This enzyme works in the lysosomes, which are compartments that digest ...
★リンクテーブル★
[★]
- 英
- beta-mannosidosis
- 関
- βマンノシドーシス
[★]
- 英
- beta-mannosidosis
- 関
- βマンノース症
[★]
マンノース症、マンノシドーシス
- 関
- mannosidase deficiency disease
[★]
β、ベータ
[★]